| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Unknown | Unknown | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Unknown | Unknown | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Unknown | Unknown |
Recent Updates
Recently added Catalysts
EyePoint, Inc.$14.72
-0.12 (-0.81%)
C 41Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.08 B
EPS
-3.50
P/E Ratio
-
Value Trade
10.29 M
SEC Financials
Q1 2026Dilution Risk
Revenue
696.00 K
R&D Expenses
72.15 M
Operating CF
-80.55 M
Total Assets
288.22 M
Total Liabilities
57.74 M
Equity
230.47 M
D/E Ratio
12,345
-0.84 %
Week
-9.26 %
1 Month
-11.32 %
3 Month
-5.14 %
6 Month
39.18 %
5 Year
-96.92 %
All Time
Cash Data
Cash Position
222.55 M
Monthly Burn
26.85 M
Runway
6.1 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.64 M
52 Week Range
5.57 - 19.11
% held by Insiders
6.81 %
% held by Institutions
103.52 %
Enterprise Value
883.84 M
Total Shares
83.87 M
Short %
18.64 %
Float Shares
81.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for EyePoint, Inc.
812Total events
5Upcoming
202Tier-1 (high impact)
2011 – 2027Coverage
Upcoming catalysts 5
Event history 807
Q3 2026
◆Enrollment CompleteDURAVYUTrial
Full enrollment expected in CAPRI trial in DME in Q3 2026
diabetic macular edemasource ↗
Q3 2026
◆Topline ReadoutDURAVYUClinical Data
Topline data for LUCIA trial
wet age-related macular degenerationsource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
Jun 3, 2026
Jun 2026
◆Topline ReadoutDURAVYUClinical Data
Topline data for LUGANO trial in wet AMD expected beginning mid-2026
wet age-related macular degenerationsource ↗
May 26, 2026
May 19, 2026
May 14, 2026
▲DSMB ReviewDURAVYUTrial
Third consecutive positive DSMC recommendation for Phase 3 wet AMD trials
wet age-related macular degenerationsource ↗
May 2, 2026
▲Enrollment MilestoneDURAVYUTrial
All active patients in treatment arm reached second DURAVYU dosing visit (Week 32)
wet age-related macular degenerationsource ↗
May 2026
▲Oral PresentationDURAVYUPresentation
Data presented at ARVO 2026 from DAVIO 2 trial in wet AMD
wet age-related macular degenerationsource ↗
May 2026
▲Preclinical PoCDURAVYUPreclinical
Preclinical data presented at ARVO 2026 demonstrating inhibition of IL-6 signaling by vorolanib
retinal diseasessource ↗
Drug Pipeline Intelligence
C41
Pipeline Score $475M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.4x
rNPV / MCap Top 58%
Micro Cap (rank 384 of 912)
Percentile RankEyePoint, Inc. carries a moderate pipeline score (41/100), with $1.7B risk-adjusted pipeline value, led by EYP-1901 in Wet Age Related Macular Degeneration (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EYP-1901 Small molecule | Diabetic Macular Edema | Phase 3 | NCT06099184 | 50% | $402M | COMPLETED | 507 | - | - | Oct 24, 2024 | LOW_RISK | Mar 4, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DURAVYU | diabetic macular edema (DME) | Phase 2 | 2025-05-07 | +10.3 letters versus +3.0 letters for aflibercept control; CST improvement Read More | EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU Phase 3 wet AMD clinical trials with over 90% of patients Read More | |
DURAVYU | diabetic macular edema (DME) | Phase 2 | 2025-05-07 | +10.3 letters versus +3.0 letters for aflibercept control; CST improvement Read More | EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU Phase 3 wet AMD clinical trials with over 90% of patients Read More | |
DURAVYU | diabetic macular edema (DME) | Phase 2 | 2025-05-07 | +10.3 letters versus +3.0 letters for aflibercept control; CST improvement Read More | EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU Phase 3 wet AMD clinical trials with over 90% of patients Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EYPT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EYPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EYPT▲ +6.6%on this news
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. has granted non-statutory stock options to three new employees as inducement awards, aligning with NASDAQ Listing Rule 5635(c)(4). A total of 39,700 shares are involved, and the option awards come with a ten-year term, vesting over four years. The company's lead product candidate, DURAVYU, is currently undergoing Phase 3 trials for wet AMD and DME, with topline data expected in mid-2026. While the company remains committed to innovation in retinal disease treatments, uncertainty remains regarding FDA approval timelines.
Read more →EYPTEyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. announced its participation in several upcoming investor conferences, which will feature fireside chats hosted by Stifel, Jefferies, and Goldman Sachs. The company aims to enhance visibility around its innovations and developments, particularly centered on its lead product candidate, DURAVYU, which is undergoing Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. Despite promising data, the FDA approval timeline for DURAVYU is still uncertain, highlighting potential risks for the company.
Read more →EYPTEyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
EyePoint, Inc. has announced a positive recommendation from the Data Safety Monitoring Committee for its Phase 3 trials of DURAVYU for wet AMD. This marks the third consecutive favorable review, suggesting a consistent safety profile ahead of the anticipated mid-2026 topline data release. With all active patients having reached the second dose visit and over 35% receiving a third dose, the company is optimistic about DURAVYU's potential impact on retinal disease treatment.
Read more →EYPTtanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com Media: Helen O'Gorman FTI Consulting helen.ogorman@fticonsulting.com
EyePoint, Inc. has received a third successive positive recommendation from the independent Data Safety Monitoring Committee for its Phase 3 trials of DURAVYU, aimed at treating wet age-related macular degeneration (AMD). Preliminary safety data from these trials indicate a continued favorable profile consistent with prior studies. All active patients have reached their second dosing visit, with over 35% having received a third dose. Topline data from the trials is anticipated in mid-2026, which could position DURAVYU as a groundbreaking therapy in this therapeutic area.
Read more →EYPTEyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. reported its Q1 2026 financial results, highlighting progress in its Phase 3 trials for DURAVYU in wet AMD and diabetic macular edema (DME). The company has over $223 million in cash, providing a runway into late 2027. Despite a significant net loss and decreased revenue, the ongoing trials are on track, with topline data expected soon.
Read more →EYPTEYEPOINT, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data)
EyePoint, Inc. reported its financial results for Q1 2026, revealing a significant decrease in net revenue while maintaining a robust cash position of $223 million. The company is advancing key Phase 3 trials for its primary product candidate, DURAVYU, in treating wet AMD and diabetic macular edema. Despite increased operating expenses and a growing net loss, the company is optimistic about its upcoming clinical data readouts starting in mid-2026. A conference call was scheduled to discuss these developments further.
Read more →EYPTEyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
EyePoint, Inc. will host a conference call on May 6, 2026, to report its first quarter financial results and discuss recent developments. The company is focused on innovative treatments for retinal diseases, particularly its lead product candidate, DURAVYU, which is under evaluation in Phase 3 trials. Topline data for wet AMD is expected in mid-2026.
Read more →EYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 16, 2026
EyePoint, Inc. announced the granting of non-statutory stock options to fourteen new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options, totaling 362,500 shares, have an exercise price of $14.63 and will vest over four years. The company is also advancing its lead product candidate, DURAVYU, in Phase 3 trials for retinal diseases.
Read more →EYPTLegal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and
EyePoint Pharmaceuticals is focusing on its investigational product DURAVYU for retinal diseases, particularly wet AMD and DME. They assert that DURAVYU is well-positioned in the market, was conditionally accepted by the FDA, and is supported by comprehensive clinical data. However, the path to regulatory approval remains uncertain, with significant risks including potential financial constraints and clinical trial outcomes. The company is aiming for key milestones in its Phase 3 clinical trials, which are essential for commercialization.
Read more →EYPTEyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. reported its financial results for Q4 and full-year 2025, highlighting significant developments in its DURAVYU programs. The company is on track for pivotal Phase 3 trial data readouts in mid-2026 for wet AMD and has initiated trials for diabetic macular edema. Despite a substantial net loss and decreased revenues, EyePoint maintains a strong cash position and has appointed a new Chief Commercial Officer to lead its launch strategy.
Read more →EYPTEYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Three Months Ended Twelve Months Ended December 31
EyePoint Pharmaceuticals reported its fourth quarter and full-year 2025 financial results, highlighting advancements in its pivotal DURAVYU trials for wet AMD and DME. The company announced a strong financial position with over $300 million in cash, supporting operations into late 2027. The appointment of Michael Campbell as Chief Commercial Officer aims to enhance the launch strategy for DURAVYU, which is expected to demonstrate its efficacy in upcoming Phase 3 data. However, the company faced significant net losses and increased operating expenses during the reporting period.
Read more →EYPTEyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
EyePoint, Inc. has announced the dosing of the first patients in its Phase 3 COMO and CAPRI trials for DURAVYU, an investigational treatment for diabetic macular edema (DME). This milestone highlights EyePoint's leadership in sustained-release ocular drug delivery. The trials are designed to evaluate DURAVYU's safety and efficacy compared to the current standard of care, with data expected in the second half of 2027.
Read more →EYPTGreen Room Communications Direct: 850-384-2833 EyePointMedia@grcomms.com
EyePoint, Inc. has announced the dosing of the first patients in two global Phase 3 clinical trials, COMO and CAPRI, for its investigational treatment, DURAVYU, aimed at diabetic macular edema (DME). This product represents a significant milestone, being the only tyrosine kinase inhibitor (TKI) currently in Phase 3 for this condition, grounded on encouraging earlier trial results. The trials aim to evaluate DURAVYU’s efficacy against existing treatments and offer potential benefits such as reduced treatment frequency and better patient adherence. Topline data is expected in the second half of 2027, following a comprehensive, structured evaluation against the current standard of care.
Read more →EYPTEyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
EyePoint, Inc. will host a conference call on March 4, 2026, to report its Q4 and full-year 2025 financial results. The company is focused on developing therapeutics for retinal diseases, with its lead product DURAVYU currently in Phase 3 trials for wet age-related macular degeneration. The FDA has conditionally accepted the proprietary name for DURAVYU, but approval is not guaranteed.
Read more →EYPTEyePoint Appoints Michael Campbell as Chief Commercial Officer
EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer. With over 30 years of experience in the ophthalmology sector, Campbell will oversee the company's commercial strategy, particularly for DURAVYU, which is in Phase 3 development for wet AMD and DME. His expertise is expected to be crucial for the product's successful launch.
Read more →EYPTEyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
EyePoint, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CFO George O. Elston leading a fireside chat. The company is focused on developing DURAVYU, an investigational treatment for retinal diseases, which is currently in Phase 3 trials. While the product shows promise, its FDA approval timeline is uncertain.
Read more →EYPTEyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 – Phase 3 programs underway for DURAVYU  in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –
EyePoint, Inc. has announced pivotal milestones and updates regarding its lead product candidate DURAVYU, aimed at treating wet AMD and Diabetic Macular Edema (DME). The company is on track for a data readout from its Phase 3 wet AMD trials in mid-2026, while first patient dosing for DME is expected in Q1 2026. EyePoint's CEO expressed confidence in the company's preparedness for NDA filing and FDA review, highlighting a significant commercial potential for DURAVYU in large retinal disease markets.
Read more →EYPTEyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
EyePoint, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. CEO Jay S. Duker will discuss the company's innovative therapeutics for retinal diseases, including DURAVYU, which is in Phase 3 trials for wet age-related macular degeneration. The company aims to enhance patient care and has a strong history of drug development.
Read more →EYPTEyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration - No changes in protocol recommended for LUGANO
EyePoint Pharmaceuticals announced a positive recommendation from the Independent Data Safety Monitoring Committee (DSMC) for its pivotal Phase 3 trials of DURAVYU, aimed at treating wet age-related macular degeneration (wet AMD). The DSMC's review confirmed the trials' safety data and no recommended changes to the protocol. With over 900 patients enrolled, the trials are evaluating DURAVYU's efficacy and safety, set to report topline data in mid-2026. This development strengthens confidence in DURAVYU's favorable safety profile, previously observed in clinical studies.
Read more →EYPT▼ -11.1%on this news
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals reported its third-quarter financial results, highlighting the full enrollment of Phase 3 trials for DURAVYU in wet AMD and DME. The company initiated a pivotal Phase 3 DME program and secured $172.5 million in financing to support its clinical programs. Despite a significant drop in revenue and increased losses, EyePoint remains optimistic about DURAVYU's potential in the retinal disease market.
Read more →EYPTEyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
EyePoint Pharmaceuticals will host a conference call on November 5, 2025, to report its third quarter financial results and discuss recent corporate developments. The company is advancing its lead product candidate, DURAVYU, which is currently in two Phase 3 trials for wet AMD and diabetic macular edema. The results from these trials are anticipated in 2026.
Read more →EYPT▼ -10.9%on this newsshared move
EyePoint Announces Pricing of Public Offering
EyePoint Pharmaceuticals has announced the pricing of a public offering of 11 million shares at $12.00 each, aiming to raise approximately $150 million. The funds will support the clinical development of DURAVYU™, an investigational treatment for retinal diseases, and other corporate initiatives. The offering is set to close around October 16, 2025, pending customary conditions.
Read more →EYPT▼ -10.9%on this newsshared move
EyePoint Announces Proposed Public Offering of Common Stock
EyePoint Pharmaceuticals has announced a proposed public offering of $150 million in common stock to support the clinical development of its lead product, DURAVYU™, for retinal diseases. The offering includes an option for underwriters to purchase an additional $22.5 million in shares. The company aims to use the proceeds for advancing clinical trials and general corporate purposes, although the offering's completion is subject to market conditions.
Read more →EYPT▼ -10.9%on this newsshared move
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
EyePoint Pharmaceuticals has initiated a pivotal Phase 3 program for DURAVYU, targeting diabetic macular edema (DME). The first patient dosing is anticipated in Q1 2026, following promising Phase 2 results that demonstrated significant improvements in vision. New preclinical data supports DURAVYU's multi-mechanism action, inhibiting both VEGF and IL-6 pathways.
Read more →EYPTEyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized – &#x
EyePoint Pharmaceuticals (EYPT) reported financial results for the second quarter of 2025, showcasing completion of Phase 3 enrollment for its DURAVYU treatment in wet AMD with over 800 patients. The company emphasized the rapid involvement of physicians and patients in the trial process, underlining interest in innovative therapies. They anticipate topline data release from the LUGANO and LUCIA trials in mid-2026 and late-2026, respectively. Despite a notable increase in net loss and operating expenses compared to the previous year, the company maintains a robust cash position aimed at sustaining its operations through 2027.
Read more →EYPTEyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
EyePoint Pharmaceuticals is set to present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference, with CEO Jay S. Duker leading a fireside chat. The company is focused on developing DURAVYU, an investigational treatment for VEGF-mediated retinal diseases, which is currently in Phase 3 trials for wet AMD. The product has shown positive results in earlier trials, and despite the promising data, its FDA approval remains uncertain. EyePoint aims to improve the lives of patients with serious retinal diseases through innovation and partnerships in the retina community.
Read more →EYPTEyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
EyePoint Pharmaceuticals, Inc. will host a conference call on August 6, 2025, to report its second quarter 2025 financial results. During the event, the company will also discuss recent developments regarding its investigational product candidate, DURAVYU, aimed at treating serious retinal diseases. The conference call will be accessible via a live webcast, and a replay will be available afterward. DURAVYU is currently undergoing pivotal Phase 3 trials for wet age-related macular degeneration, with results expected in 2026.
Read more →EYPTEyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration – LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating co
EyePoint Pharmaceuticals has successfully completed enrollment for the LUCIA trial in their Phase 3 pivotal program for DURAVYU, aimed at treating wet age-related macular degeneration (AMD). This achievement underscores the strong engagement from both patients and physicians, as illustrated by the rapid recruitment of over 400 participants within seven months. Interim safety analyses have shown no serious adverse events, allowing the trials to proceed as planned. Results for topline data from LUGANO are expected in mid-2026, with LUCIA results to follow closely after.
Read more →EYPTEyePoint Completes Enrollment in the Pivotal Phase 3 LUGANO Trial of DURAVYU TM for the Treatment of Wet Age-Related Macular Degeneration – Over 400 patients have been enrolled and randomized over a seven-month pe
EyePoint Pharmaceuticals has successfully completed enrollment in the LUGANO pivotal Phase 3 trial for its treatment DURAVYU, targeting wet age-related macular degeneration (wet AMD). With over 400 patients enrolled in just seven months, this trial has achieved one of the fastest enrollment rates in its category. Topline results are expected in mid-2026, following a promising Phase 2 trial that demonstrated significant efficacy and safety. The company aims to bring a new treatment option for patients suffering from wet AMD, addressing challenges posed by conventional therapies.
Read more →EYPTEyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals has successfully completed enrollment for over 400 patients in its Phase 3 LUGANO trial of DURAVYU, aimed at treating wet age-related macular degeneration (AMD). This trial represents one of the fastest enrollments for a pivotal Phase 3 trial in this indication. With topline data expected in mid-2026, the company continues to show promise in advancing its innovative therapeutic aimed at improving patient care in the retinal sector. Additionally, the ongoing LUCIA trial is projected to complete its enrollment by the third quarter of 2025.
Read more →EYPT▲ +7.2%on this news
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals announced the granting of non-statutory stock options to seven new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). The stock options allow for the purchase of 136,700 shares of common stock, set at an exercise price of $5.72 per share, with a vesting schedule spanning four years. The grants have been approved by the Compensation Committee and are intended to attract talent as the company continues to focus on developing therapeutics for retinal diseases. EyePoint's lead candidate, DURAVYU, is currently in Phase 3 trials for wet AMD.
Read more →EYPTEyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU Phase 3 wet AMD clinical trials with over 90% of patients
EyePoint Pharmaceuticals reported strong financial results for Q1 2025, including significant trial progress for DURAVYU in wet AMD. Enrollment in pivotal Phase 3 trials has exceeded expectations, with over 90% participation in one trial. The company is financially solid, with $318 million in cash, allowing it to sustain operations into 2027. They also announced compelling efficacy results from previous trials, enhancing confidence in DURAVYU as a leading treatment for retinal diseases.
Read more →EYPTEyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
EyePoint Pharmaceuticals, Inc. plans to release its first-quarter 2025 financial results on May 7, 2025, during a conference call. The company is focused on developing therapies for serious retinal diseases, leveraging its proprietary Durasert E™ technology. Their lead product, DURAVYU, is currently in Phase 3 clinical trials for wet AMD. Despite positive developments, the product's approval timeline remains uncertain, as it has not yet received FDA approval.
Read more →EYPTEyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
EyePoint Pharmaceuticals announced its participation in the 2025 RBC Capital Markets Ophthalmology Conference, where CEO Jay S. Duker will discuss the company's advancements. EyePoint is actively developing its lead product candidate, DURAVYU, which is currently in Phase 3 clinical trials for wet age-related macular degeneration (AMD) and has shown positive outcomes in a Phase 2 trial for diabetic macular edema. The company's use of proprietary Durasert technology for sustained drug delivery highlights its innovative approach in treating serious retinal diseases. However, the investigational status of DURAVYU means FDA approval is still pending.
Read more →EYPT▲ +8.2%on this news
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments – Enrollment exceeding expectations in DURAVYU Phase 3 wet AMD clinical trials with LUGANO over 50%
EyePoint Pharmaceuticals reported its financial results for Q4 and the full year of 2024, highlighting promising developments in clinical trials for its drug DURAVYU. Enrollment in the Phase 3 LUGANO and LUCIA trials for wet AMD has exceeded expectations. Positive results were announced for the Phase 2 VERONA trial in diabetic macular edema, with significant improvements in vision and fluid reduction. Despite a net loss of $130.9 million over the year, the company maintains a strong cash position, allowing it to fund operations into 2027.
Read more →EYPT▲ +6.3%on this news· ran to +25% by day 3shared move
The Leader in Sustained Release Drug Delivery for Retinal Disease 2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Durasert features robust safety profile across multiple indications Compelling DAVIO 2 data enabl
EyePoint Pharmaceuticals recently presented promising data on its sustained release drug DURAVYU for treating diabetic macular edema (DME). The Phase 2 VERONA clinical trial demonstrated significant improvements in best-corrected visual acuity compared to standard aflibercept treatment. The drug showcases a robust safety profile and aims to improve treatment adherence through less frequent dosing. EyePoint's innovative approach positions DURAVYU as a potential game-changer in DME management, supporting better patient outcomes.
Read more →EYPTEyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced it will report its fourth quarter and full-year 2024 financial results on March 5, 2025, via a conference call and live webcast. The company is focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, in Phase 3 trials for wet age-related macular degeneration. Additionally, positive results from a Phase 2 trial in diabetic macular edema will inform upcoming regulatory discussions. EyePoint's proprietary Durasert technology enhances drug delivery potential in ophthalmic applications.
Read more →EYPTEyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
EyePoint Pharmaceuticals announced an upcoming corporate presentation at the TD Cowen 45th Annual Health Care Conference, scheduled for March 4, 2025. The presentation will focus on updates regarding the ongoing Phase 3 pivotal program of DURAVYU, intended for wet AMD, and subgroup analyses from a Phase 2 trial for diabetic macular edema (DME). Additionally, based on encouraging Phase 2 results, EyePoint plans to engage with regulatory agencies in 2025 to discuss a pivotal program for DME. The company utilizes its proprietary Durasert E™ technology for drug delivery.
Read more →EYPTEyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU TM for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - Primary endpoint achieved by both DURAVYU doses (1.34
EyePoint Pharmaceuticals announced encouraging results from the Phase 2 VERONA clinical trial of DURAVYU, achieving both primary and secondary endpoints for diabetic macular edema (DME). The trial displayed significant improvements in best corrected visual acuity and anatomical metrics, while maintaining a favorable safety profile without serious adverse events. The data supports future pivotal trials, with a Phase 3 non-inferiority study anticipated to begin by late 2025, which may position DURAVYU as a leading treatment option in retinal disease care. The findings address significant patient needs in managing DME, a prevalent condition linked to diabetes.
Read more →EYPTEyePoint to Present at Guggenheim SMID Cap Biotech Conference
EyePoint Pharmaceuticals, Inc. has announced its participation in the Guggenheim SMID Cap Biotech Conference, where CEO Jay S. Duker will engage in a fireside chat. The company is currently advancing its lead product candidate, DURAVYU, through Phase 3 clinical trials for wet age-related macular degeneration, with topline data expected in 2026. Additionally, EyePoint's pipeline includes other investigational therapies utilizing its proprietary Durasert technology. The company focuses on innovative treatments for serious retinal diseases.
Read more →EYPT▼ -7.1%on this newsshared move
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
EyePoint Pharmaceuticals has provided an update on its anticipated developments for 2025, focusing on its lead candidate DURAVYU for retinal diseases. Enrollment for the Phase 3 trials in wet AMD is progressing ahead of schedule, with the full data for the Phase 2 VERONA trial in DME expected in the first quarter of 2025. The company announced a strong cash position that will support operations through 2027 and welcomed Reginald J. Sanders, M.D., to its Board of Directors. EyePoint is positioned for future success with promising clinical trial results and robust market opportunities.
Read more →EYPT▼ -7.1%on this newsshared move
Legal Disclaimers 2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
EyePoint Pharmaceuticals, Inc. presented forward-looking statements at the J.P. Morgan Healthcare Conference regarding their product DURAVYU, which shows promising interim data for treating diabetic macular edema (DME). The company discussed its clinical trial results, highlighting the potential benefits and safety profile of DURAVYU compared to existing therapies. However, uncertainties regarding regulatory approvals and potential risks were also emphasized, highlighting the variability in future outcomes and funding challenges.
Read more →EYPTEyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
EyePoint Pharmaceuticals has appointed Dr. Reginald J. Sanders, a leading retina specialist, to its Board of Directors. His extensive experience in ophthalmology and leadership within the retina community is expected to significantly contribute to EyePoint's clinical initiatives. The company is currently progressing with pivotal trials for its treatment DURAVYU aimed at serious retinal diseases. Dr. Sanders expresses enthusiasm about the potential of EyePoint’s therapeutic innovations.
Read more →EYPT▲ +5.4%on this news
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EyePoint Pharmaceuticals, Inc. will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. Jay S. Duker, M.D., CEO, will deliver the presentation, highlighting the company's commitment to developing innovative therapeutics for retinal diseases. Notably, its lead product DURAVYU is currently in Phase 3 trials for wet AMD and Phase 2 for diabetic macular edema. The company expects to release important clinical data in early 2025 and 2026.
Read more →EYPTEyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU TM for the Treatment of Wet Age-Related Macular Degeneration – Topline data for Phase 3 pivotal program anticipated i
EyePoint Pharmaceuticals has announced the dosing of the first patient in its second global Phase 3 clinical trial, LUCIA, for its investigational therapy DURAVYU aimed at treating wet age-related macular degeneration (wet AMD). This trial follows a successful first pivotal trial, LUGANO, and signifies EyePoint's commitment to developing innovative therapies. Both trials are designed to provide insights into the efficacy and safety of DURAVYU while reducing the treatment burden faced by patients. Topline data from these trials is anticipated in 2026.
Read more →EYPTEyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments – Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sus
EyePoint Pharmaceuticals has reported its financial results for Q3 2024, highlighting encouraging interim data for its DURAVYU treatment in diabetic macular edema (DME), which showed significant visual acuity improvements. The company has also commenced its Phase 3 LUGANO trial for wet AMD and completed a successful $161 million equity financing. Despite a reduction in revenue and an increased net loss compared to the previous year, EyePoint remains optimistic about its pipeline and future clinical trials.
Read more →EYPTEyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
EyePoint Pharmaceuticals announced its participation in several upcoming investor conferences, including Guggenheim's Healthcare Innovation Conference and the UBS Global Healthcare Conference. The company aims to enhance its visibility and stakeholder engagement through these platforms. EyePoint is focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU currently in pivotal Phase 3 trials for wet AMD. The company anticipates important clinical trial data in early 2025 and 2026.
Read more →EYPTEyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
EyePoint Pharmaceuticals has successfully completed an upsized public offering, closing on 14,636,363 shares of common stock at a price of $11.00 per share. This offering, which included the full exercise of underwriters' options, generated approximately $161 million in gross proceeds. The company plans to use the funds to advance the clinical development of its lead product, DURAVYU, intended for treating conditions such as wet age-related macular degeneration and diabetic macular edema, as well as other pipeline initiatives.
Read more →EYPTEyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
EyePoint Pharmaceuticals has announced a public offering of 12,727,273 shares of its common stock, priced at $11.00 per share, to raise approximately $140 million. The company intends to use the net proceeds to further the clinical development of DURAVYU for retinal diseases like wet AMD and DME, and to support its early-stage pipeline. The offering's closing is expected on or around October 31, 2024, pending satisfaction of customary closing conditions. EyePoint's clinical pipeline includes ongoing Phase 3 and Phase 2 trials for its lead candidate DURAVYU, which aims to provide sustained delivery treatment for serious retinal conditions.
Read more →EYPT▲ +27.6%on this newsshared move
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
EyePoint Pharmaceuticals has announced a proposed public offering of $125 million in common stock, with an additional option for underwriters to purchase $18.75 million more. The funds raised will be directed towards advancing the clinical development of DURAVYU, aimed at treating wet age-related macular degeneration and diabetic macular edema, alongside supporting earlier-stage pipeline initiatives. The offering is contingent upon market conditions, leaving the completion and terms uncertain, and comes as EyePoint aims to push its key product closer to potential FDA approval, which remains unpredictable at this stage.
Read more →EYPT▲ +27.6%on this newsshared move
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU TM for Diabetic Macular Edema - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA
EyePoint Pharmaceuticals has reported positive interim results from its Phase 2 VERONA clinical trial evaluating DURAVYU for diabetic macular edema (DME). The interim 16-week data showed DURAVYU 2.7mg led to a significant improvement in best-corrected visual acuity and anatomical control compared to the aflibercept control. The trial's outcomes, including gains in central subfield thickness and a continued positive safety profile, suggest DURAVYU may address critical unmet needs in DME treatment. Full topline results are expected in Q1 2025.
Read more →EYPTEyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYU TM for the Treatment of Wet Age-Related Macular Degeneration – Second Phase 3 LUCIA pivotal trial first pat
EyePoint Pharmaceuticals has dosed the first patient in the global Phase 3 LUGANO clinical trial for DURAVYU, an investigational treatment for wet age-related macular degeneration. This milestone reflects the company's dedication to improving patient care through innovative therapies. Concurrently, the LUCIA trial is anticipated to initiate by the end of 2024, with topline data expected in 2026. Both trials aim to assess the efficacy and safety of DURAVYU, potentially transforming treatment strategies for this condition.
Read more →EYPTEyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors - Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU TM in w
EyePoint Pharmaceuticals has appointed Fred Hassan, a seasoned industry leader, to its Board of Directors, strengthening its leadership team ahead of pivotal Phase 3 trials for DURAVYU in wet age-related macular degeneration. Hassan's extensive experience in the biopharmaceutical sector is anticipated to provide valuable strategic insights as the company focuses on advancing innovative treatments for retinal diseases. The appointment comes as the company faces the resignation of two directors transitioning to new roles at Merck & Co., presenting a potential challenge for leadership continuity. With the first patient dosing expected in 2024, EyePoint aims to address significant unmet needs in this therapeutic area.
Read more →EYPT▲ +5.9%on this news
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference scheduled for August 15, 2024. President and CEO Jay S. Duker will present insights on the evolving therapeutic landscape of age-related macular degeneration (AMD). The company's lead product, DURAVYU, is currently in Phase 2 trials for retinal diseases and aims to enter pivotal Phase 3 trials by 2024. EyePoint's commitment to innovative therapeutics is underscored by the potential impact of its Durasert technology in the treatment of serious retinal conditions.
Read more →EYPTEyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments – Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU in wet AMD on track for first
EyePoint Pharmaceuticals announced its financial results for Q2 2024, revealing a net revenue increase driven mostly by royalties and collaborations despite a drop in net product revenue. The company highlighted progress on its DURAVYU treatment for wet AMD, supported by positive Phase 2 data and upcoming Phase 3 trials. Cash reserves are expected to fund operations through essential clinical data releases until 2026. Increased research and development expenses contributed to larger net losses in the latest quarter.
Read more →EYPTEyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint Pharmaceuticals announced significant advancements in its lead program DURAVYU, including positive twelve-month data from the Phase 2 DAVIO 2 clinical trial for wet AMD. The company is on track to initiate pivotal Phase 3 trials in the second half of 2024, following a favorable End of Phase 2 meeting with the FDA. DURAVYU aims to provide a sustained release treatment option for patients with retinal diseases, and the company expressed optimism about its potential market impact.
Read more →EYPTLegal Disclaimers 2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
EyePoint Pharmaceuticals announced favorable preliminary results for DURAVYU from the Phase 2 DAVIO 2 clinical trial. The data indicates no serious adverse events associated with DURAVYU, and there were no occurrences of insert migration or retinal occlusive vasculitis. The patient discontinuation rate was low, with none of the discontinuations related to the treatment. This positive safety profile suggests potential for further development of DURAVYU in ocular treatments.
Read more →EYPTEyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
EyePoint Pharmaceuticals is set to host an R&D Day on June 26, 2024, focused on advancements in retinal disease therapeutics. The event will feature discussions on the investigational therapy DURAVYU, previously known as EYP-1901, which has shown positive Phase 2 trial results. Key opinion leaders will present insights, and updates regarding upcoming trials will be shared. The company emphasizes its commitment to improving treatments for patients with VEGF-mediated retinal conditions.
Read more →EYPT▲ +6.2%on this news
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
EyePoint Pharmaceuticals announced that Jay S. Duker, M.D., will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. The company focuses on therapeutics for serious retinal diseases, with its lead candidate, DURAVYU, using proprietary Durasert technology for sustained intraocular drug delivery. While the company's innovations show promise, the FDA's approval for DURAVYU is still pending and its timeline remains uncertain.
Read more →EYPTEyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments – Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU in wet
EyePoint Pharmaceuticals has reported its first quarter financial results for 2024, showcasing an $11.7 million revenue, which marks an increase from $7.7 million in the same quarter of 2023. Notably, the company indicated strong financial health with $299 million in cash, sufficient to support ongoing clinical trials through 2026. Furthermore, the company is set to initiate the pivotal Phase 3 LUGANO trial for DURAVYU in wet AMD later this year, despite recent challenges, including the PAVIA trial not meeting its primary endpoint. Key updates also include a planned R&D Day for June 26, 2024, where further advancements in their pipeline will be discussed.
Read more →EYPT▼ -43.3%on this newsshared move
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals announced topline data from its Phase 2 PAVIA trial evaluating DURAVYU in non-proliferative diabetic retinopathy (NPDR). While the drug demonstrated stable or improved disease severity and a favorable safety profile, it did not meet its primary endpoint. The company intends to review the full 12-month results to determine the next steps for DURAVYU. EYPT is also preparing for upcoming pivotal trials in wet AMD, emphasizing their commitment to developing innovative therapies for retinal diseases.
Read more →EYPT▼ -43.3%on this newsshared move
(FDA) regulatory approval of DURAVYU and EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service pro
EyePoint Pharmaceuticals announced topline data from the Phase 2 PAVIA trial of DURAVYU in patients with non-proliferative diabetic retinopathy. The results indicated that DURAVYU showed a favorable safety profile and reduced NPDR progression after nine months, but did not meet the primary efficacy endpoint. Further analysis will be conducted to assess its potential as a treatment. The company is also preparing for upcoming pivotal trials in wet AMD to continue advancing DURAVYU's development.
Read more →EYPTEyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
EyePoint Pharmaceuticals (EYPT) has expanded its Scientific Advisory Board by appointing leading retinal specialists, which will support its upcoming Phase 3 clinical trials for the investigational product DURAVYU in wet age-related macular degeneration (AMD). The company is set to initiate these pivotal trials in the second half of 2024. Additionally, the FDA has conditionally accepted the trade name DURAVYU for EYP-1901, marking a significant step forward in the product's development. The newly appointed specialists aim to aid in global strategy and advance the company's research efforts in treating serious retinal diseases.
Read more →EYPTEyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals (EYPT) reported its financial results for Q4 and the full year of 2023, highlighting significant achievements including positive data from the Phase 2 DAVIO 2 trial of EYP-1901, which met all primary and secondary endpoints. The company also initiated the Phase 2 VERONA trial and is anticipating further data in 2024. Despite a decrease in net product revenue due to exiting its commercial business, EyePoint reported $331 million in cash, expected to sustain operations through upcoming trials. Management changes, including the appointment of a new Chief Medical Officer, support ongoing corporate development.
Read more →EYPT▼ -7.5%on this newsshared move
consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a
EyePoint Pharmaceuticals has announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as the new Chief Medical Officer. Dr. Ribeiro, who has a strong background in retinal diseases, previously served at Apellis Pharmaceuticals. The company is set to report topline data from the Phase 2 PAVIA trial of EYP-1901 in moderately severe-to-severe NPDR in the second quarter of 2024, and will initiate its first Phase 3 trial for wet AMD in the second half of 2024. EyePoint continues to strengthen its leadership as it advances its clinical trials and pipeline programs.
Read more →EYPT▼ -7.5%on this newsshared move
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
EyePoint Pharmaceuticals announced the appointment of Dr. Ramiro Ribeiro as the new Chief Medical Officer, succeeding Dr. Dario Paggiarino. Dr. Ribeiro has a strong clinical background and is expected to enhance the company's leadership team as it approaches key clinical milestones. The company plans to report topline data from the Phase 2 PAVIA clinical trial for EYP-1901 in the second quarter of 2024 and initiate its first Phase 3 LUGANO trial in the latter half of 2024 for wet AMD. This leadership change comes at a crucial time as EyePoint aims to advance its pipeline of therapies for retinal diseases.
Read more →EYPTEyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced a conference call scheduled for March 7, 2024, to discuss its fourth quarter and full-year 2023 financial results. This presentation will also highlight recent corporate developments. The company focuses on therapeutics aimed at improving the lives of patients with serious retinal diseases, utilizing advanced technologies like their Durasert E™ for sustained drug delivery. EyePoint's lead candidate is EYP-1901, which targets VEGF-mediated retinal diseases.
Read more →EYPTEyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals has announced promising results from subgroup analyses of the Phase 2 DAVIO 2 clinical trial for EYP-1901, aimed at treating wet age-related macular degeneration. The data highlighted the investigational drug's numerical superiority in visual acuity and strong safety profile compared to aflibercept. EyePoint anticipates starting Phase 3 trials in the latter half of 2024 and expects additional data from the ongoing PAVIA trial on diabetic retinopathy soon.
Read more →EYPTEyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
EyePoint Pharmaceuticals recently announced that George Elston, the Executive VP and CFO, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The event will feature discussions on the company's innovative therapeutics aimed at improving patient outcomes for serious retinal diseases. A live webcast will be available, allowing wider accessibility for interested parties. The participation underscores EyePoint's commitment to highlighting its advancements in retinal disease treatments.
Read more →EYPT▼ -5.8%on this newsshared move
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
EyePoint Pharmaceuticals has commenced the Phase 2 VERONA clinical trial for EYP-1901, dosing its first patient. This investigational therapy aims to address the treatment needs of diabetic macular edema (DME), with a focus on delivering longer-acting solutions compared to current options. The company highlights the importance of this trial in improving patient outcomes for retinal diseases. Additional data and milestones from related trials are expected throughout 2024 and into 2025.
Read more →EYPTLegal Disclaimers 2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
EyePoint Pharmaceuticals is currently conducting a Phase 2 clinical trial called the VERONA trial, which focuses on the efficacy and safety of EYP-1901 for patients with diabetic macular edema (DME). This open-label trial evaluates two dosing regimens of EYP-1901 compared to aflibercept. The primary endpoint is the time to the need for a supplemental anti-VEGF injection up to 24 weeks. Topline data is expected in the first quarter of 2025, which will help inform future clinical studies.
Read more →EYPTEyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EyePoint Pharmaceuticals, Inc. has announced that its President and CEO, Jay S. Duker, M.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company focuses on developing therapeutics for serious retinal diseases, including its lead product candidate, EYP-1901. Additionally, the company utilizes proprietary Durasert technology for sustained drug delivery. A webcast of the presentation will be available on the company's website for those unable to attend the live event.
Read more →EYPT▲ +177.5%on this newsshared move
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints - Both EYP-1901 cohorts demonstrated a statistically non-inferi
EyePoint Pharmaceuticals announced positive topline data from its Phase 2 DAVIO 2 trial for EYP-1901, an investigational treatment for wet AMD. The trial achieved all primary and secondary endpoints, demonstrating statistical non-inferiority to aflibercept with a favorable safety profile and no related serious adverse events. Key findings included a significant reduction in treatment burden, with a majority of eyes being supplement-free after six months. The company now plans to initiate Phase 3 trials, supported by the strong Phase 2 results.
Read more →EYPT▼ -5.6%on this news
Forward-Looking Statements 2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Ac
EyePoint Pharmaceuticals, Inc. is focusing on tailoring dosing schedules to meet individual patient needs while managing chronic diseases. The company's EYP-1901 is highlighted for its potential to provide greater flexibility in patient management. The approach aims to combine short- and long-acting drugs with different mechanisms of action to optimize therapy and improve patient flow during visits.
Read more →EYPT▲ +20.3%on this news
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments – Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical tr
EyePoint Pharmaceuticals reported its third quarter financial results, highlighting positive safety data for its candidate EYP-1901 in ongoing Phase 2 clinical trials. The company anticipates topline data for the DAVIO 2 trial in wet AMD by December 2023 and for the PAVIA trial in diabetic retinopathy by the second quarter of 2024. Despite a decrease in net product revenue due to a franchise sale, EyePoint continues strategic initiatives to enhance corporate leadership and drive future growth.
Read more →EYPT▲ +5.4%on this news· ran to +36% by day 3shared move
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
EyePoint Pharmaceuticals, Inc. announced a virtual key opinion leader event scheduled for November 9, 2023, to discuss the potential of EYP-1901 in treating wet age-related macular degeneration (wet AMD). The event will include insights from leading retinal experts and focus on current treatment landscapes and upcoming data from the DAVIO 2 trial. EYP-1901, featuring a unique delivery technology, has shown positive results in earlier trials, reinforcing EyePoint's commitment to improving therapies for retinal diseases.
Read more →EYPTEyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023
EyePoint Pharmaceuticals announced its upcoming presentations at several key medical meetings, including the Eyecelerator and the American Academy of Ophthalmology Annual Meeting. CEO Jay S. Duker will present safety data from ongoing clinical trials for EYP-1901, demonstrating good safety outcomes. Additionally, Dr. Robert L. Avery will present data showcasing the efficacy of vorolanib in treating retinal diseases. These events reflect EyePoint's ongoing efforts in advancing treatments for patients suffering from retinal conditions.
Read more →EYPT▼ -14.2%on this newsshared move
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023
EyePoint Pharmaceuticals, Inc. has announced a conference call scheduled for November 1, 2023, to report its third quarter financial results. The event will highlight recent corporate developments and can be accessed through a live webcast. The company focuses on therapeutics for retinal diseases and has an investigational treatment, EYP-1901, currently in Phase 2 clinical trials, demonstrating its commitment to innovation in this field.
Read more →EYPTEyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team - Stuart Duty appointed to EyePoint's Board of Directors – - George Elston promoted to Executive Vice President
EyePoint Pharmaceuticals has appointed Stuart Duty to its Board of Directors and promoted George Elston to Executive Vice President. Stuart Duty brings over 30 years of experience in biotech finance, which the company aims to leverage as it advances its pipeline, including the upcoming Phase 2 data for EYP-1901. George Elston, who has been part of EyePoint since 2019, played a significant role in the company’s growth and is expected to contribute further in his new position. The company is focused on developing innovative therapies for retinal diseases, with a promising pipeline on the horizon.
Read more →EYPTForward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertain
The investor presentation from EYPT outlines forward-looking statements regarding the clinical development of their product candidate EYP-1901 for serious eye diseases. The presentation highlights anticipated Phase 2 trial milestones, including data expected in December 2023 and Q2 2024. Despite a strong cash position of $142.5M, the company acknowledges multiple risks such as reliance on clinical trials, manufacturing, and market stability that could impact their future performance. The safety profile of EYP-1901 from the Phase 1 trial shows promising results with minimal adverse events reported.
Read more →EYPT▲ +16.2%on this newsshared move
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023
EyePoint Pharmaceuticals has reported positive interim safety data for its lead product candidate, EYP-1901, in both the ongoing Phase 2 PAVIA and DAVIO 2 clinical trials. The data indicates that EYP-1901 has been well tolerated, with no serious adverse events reported. Approximately 170 patients have been treated in the trials, with follow-up showing a promising safety profile. The company plans to share topline results from both trials in late 2023 and early 2024, indicating progress in addressing serious eye disorders.
Read more →EYPT▲ +6.2%on this news
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of
EyePoint Pharmaceuticals announced positive interim safety data for its lead product candidate EYP-1901 from the ongoing Phase 2 PAVIA and DAVIO 2 clinical trials. The trials assess EYP-1901's potential to treat significantly debilitating eye disorders. The data indicates that the treatment has been well tolerated with no serious adverse events reported. EyePoint is on schedule to release topline results for the DAVIO 2 trial in December 2023 and the PAVIA trial in Q2 2024.
Read more →EYPT▲ +6.1%on this news
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
EyePoint Pharmaceuticals, Inc. will participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on August 16, 2023. Jay S. Duker, the company's President and CEO, will present a panel discussion focused on sustained treatment for Wet AMD. Attendees will have access to a live webcast and an archived replay of the panel discussion for 90 days after the event. EyePoint is committed to developing therapeutics for serious eye conditions using its Durasert technology.
Read more →EYPTEyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments –Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remai
EyePoint Pharmaceuticals reported its second quarter 2023 financial results, highlighting significant progress in its Phase 2 DAVIO 2 clinical trial for EYP-1901 aimed at treating wet age-related macular degeneration, with topline data expected in December 2023. The company successfully sold its YUTIQ franchise for $82.5 million, allowing it to retire bank debt and extend its cash runway into 2025. Despite a revenue decline due to the sale of the YUTIQ franchise, EyePoint remains focused on its lead pipeline program, navigating through a challenging financial landscape while showcasing strong investor interest in its trials.
Read more →EYPTEyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit - Interim safety data from the Phase 2 DAVIO 2 trial continues
EyePoint Pharmaceuticals presented interim safety data from its Phase 2 DAVIO 2 clinical trial at the OIS Retina Innovation Summit. The data indicates that EYP-1901, a treatment for wet AMD, is well tolerated, with no drug-related ocular or systemic serious adverse events reported. Additionally, patient baseline characteristics have improved relative to the previous trial phase, and the company anticipates sharing topline results in December 2023. However, there were two ocular serious adverse events unrelated to the study drug, highlighting some risks still present in the clinical trial process.
Read more →EYPT▼ -5.9%on this newsshared move
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
EyePoint Pharmaceuticals has announced that it will report its second quarter 2023 financial results on August 2, 2023. The report will be followed by a conference call and live webcast at 8:30 a.m. ET. The company is focused on developing therapeutics for serious eye disorders, leveraging its erodible Durasert technology for sustained drug delivery. In addition, the company will highlight recent corporate developments during the event.
Read more →EYPT▲ +13.3%on this news· ran to +35% by day 3
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition – Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy
EyePoint Pharmaceuticals has appointed Dr. Jay S. Duker as the new Chief Executive Officer, transitioning from his previous role as Chief Operating Officer. Nancy S. Lurker moves to Executive Vice Chair as part of a long-term succession plan. Dr. Duker, who has extensive experience in ophthalmology and has been with the company in various roles for several years, expressed enthusiasm about advancing EyePoint's clinical pipeline and focus on sustaining ocular drug delivery. The leadership change comes at a pivotal time for the company, with promising clinical trials and a strengthened financial position.
Read more →EYPTEyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy – Significant investigator and patient interest drove strong recruitment of 77 pa
EyePoint Pharmaceuticals has successfully completed enrollment in its Phase 2 PAVIA clinical trial for EYP-1901, aimed at treating non-proliferative diabetic retinopathy (NPDR). The trial exceeded its target by enrolling 77 patients, and topline data is expected in the second quarter of 2024. The investigational treatment, designed for long-acting efficacy, could significantly reduce the treatment burden for patients who currently receive no active therapy until complications arise. EyePoint aims to address a substantial unmet need in NPDR management with this novel approach.
Read more →EYPTEyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
EyePoint Pharmaceuticals, Inc. will present an overview at the Jefferies Healthcare Conference on June 7, 2023. George Elston, the Chief Financial Officer, will lead the presentation that can be accessed via a live webcast and an archived replay afterward. The company focuses on developing therapies for serious eye disorders, with its Durasert technology being central to its product offerings.
Read more →EYPTEyePoint Pharmaceuticals Announces Sale of YUTIQ to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties –$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024  
EyePoint Pharmaceuticals has entered a definitive agreement to sell YUTIQ to Alimera Sciences for $82.5 million, including a $75 million upfront payment and additional royalties. This strategic sale will enable EyePoint to retire all their outstanding bank debt and extend their cash runway into 2025. Alimera will take over global rights for YUTIQ outside specific regions in Asia while EyePoint will continue to receive royalties from its sales. This move reflects EyePoint's shift toward focusing solely on drug development for serious eye diseases.
Read more →EYPT▲ +21.7%on this news
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments – Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in
EyePoint Pharmaceuticals reported its first quarter 2023 financial results, highlighting the completion of enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial for EYP-1901, which showed exceptional interest with 160 patients enrolled. The company also announced a significant 60% increase in YUTIQ revenue compared to the same quarter last year, totaling $7.4 million. However, despite these successes, the company faced a net loss of $21.2 million this quarter, reflecting financial challenges following the discontinuation of DEXYCU. Management expects their current cash reserves will sustain operations through the second half of 2024.
Read more →EYPT▲ +11.4%on this news
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
EyePoint Pharmaceuticals, Inc. has announced a conference call and webcast scheduled for May 3, 2023, where it will report its financial results for the first quarter of 2023. The call will also highlight recent corporate developments. EyePoint is focused on developing therapeutics for serious eye disorders and is advancing its investigational drug EYP-1901 in Phase 2 clinical trials, utilizing its unique Durasert drug delivery platform.
Read more →EYPT▲ +24.1%on this news· ran to +40% by day 3
EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD - Significant investigator and patient interest drove strong recruitment, ex
EyePoint Pharmaceuticals has successfully completed enrollment in its Phase 2 DAVIO 2 clinical trial for EYP-1901, surpassing its target by including 160 patients. The trial focuses on providing a six-month maintenance treatment for wet age-related macular degeneration (AMD). The company anticipates topline data to be released in Q4 2023, which will be pivotal for the design of future Phase 3 trials. The success in patient enrollment reflects significant interest from both investigators and participants, underscoring the unmet need for effective treatment options in wet AMD management.
Read more →EYPTEyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
EyePoint Pharmaceuticals will present multiple scientific findings at the 2023 ARVO Annual Meeting, focusing on the investigational drug EYP-1901 and the YUTIQ therapy. The presentations will highlight the positive neuroprotective effects of vorolanib in treating retinal disease, as well as effective treatment outcomes for chronic uveitis. Notably, preclinical data indicate a new mechanism of action for EYP-1901 that could improve patient outcomes in chronic retinal disorders. The company is also advancing its phase 2 clinical studies for EYP-1901 in conditions like wet AMD and diabetic retinopathy.
Read more →EYPT▼ -8.8%on this news
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments – Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated
EyePoint Pharmaceuticals reported its financial results for Q4 and the full year of 2022, highlighting a net product revenue increase of 13% year-over-year. The company is advancing EYP-1901 in two Phase 2 clinical trials for wet AMD and NPDR, with topline data expected by year-end 2023. While the company reported a significant net loss of $102.3 million for the year, it maintains a cash runway projected into the second half of 2024. Additionally, a lease agreement for a new manufacturing facility is set to enhance product supply capabilities.
Read more →EYPTEyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert Technology for Sustained Intraocular Delivery in Geographic Atrophy
EyePoint Pharmaceuticals and Rallybio Corporation have announced a research collaboration to explore the combination of Rallybio's C5 inhibitor with EyePoint's Durasert technology. This partnership aims to investigate a sustained intraocular delivery system as a potential long-acting treatment for geographic atrophy, an advanced form of age-related macular degeneration that can lead to irreversible vision loss. Both companies express optimism about the therapeutic synergy and the potential to improve treatment options for affected patients, given the limitations of current therapies.
Read more →EYPT▼ -5.7%on this newsshared move
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023
EyePoint Pharmaceuticals, Inc. will report its fourth quarter and full-year 2022 financial results on March 2, 2023. The company will host a conference call and live webcast to discuss these results and recent developments. EyePoint is focused on developing therapeutics for serious eye disorders and is known for its Durasert technology, which supports sustained intraocular drug delivery. The company is headquartered in Watertown, Massachusetts.
Read more →EYPTEyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ  – State-of-the-art cGMP manufacturing facility t
EyePoint Pharmaceuticals has entered a lease agreement to construct a 40,000-square-foot commercial manufacturing facility in Northbridge, Massachusetts, aimed at supporting global product supply for EYP-1901 and YUTIQ. The facility is expected to be operational in the second half of 2024 and will comply with GMP standards to meet regulatory approvals. The company will receive approximately $1.9 million in state and local tax incentives and will start paying rent only upon occupation of the facility. This strategic move is expected to enhance manufacturing capacity and further advance the company's retinal disease-focused pipeline.
Read more →EYPTEyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines
EyePoint Pharmaceuticals has provided an update on its business operations and key clinical timelines for 2023, focusing on its lead product candidate, EYP-1901. The company anticipates topline data from the Phase 2 DAVIO 2 trial for wet AMD by 4Q 2023, with ongoing positive outcomes from earlier trials. Additionally, EyePoint expects its 2022 net product revenue to surpass $39.5 million. However, the company faces challenges due to a reduction in Medicare reimbursement for its DEXYCU product, which could impact its revenue stream.
Read more →EYPT▼ -8.8%on this newsshared move
EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer
EyePoint Pharmaceuticals has promoted Jay S. Duker, M.D. to the position of President and Chief Operating Officer, while he continues to serve as COO. Dr. Duker will oversee regulatory affairs in addition to his existing responsibilities. The company has achieved notable advancements in its product pipeline, particularly reporting positive data from the Phase 1 DAVIO trial and beginning two Phase 2 trials for EYP-1901, a treatment for ocular conditions.
Read more →EYPTEyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines – Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in P
EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR
Read more →EYPT▲ +8%on this newsshared move
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT) on behalf of EyePoint stockholders.
Read more →EYPT▼ -5.4%on this newsshared move
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments – Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopa
Read more →EYPTEyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a confere
Read more →EYPTEyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy WATERTOWN, Mass., September 29, 2022 (GLOBE NEWSWIRE) EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical co
Read more →EYPTEyePoint Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors that the firm has initiat
Read more →EYPTEyePoint Pharmaceuticals Shareholder News: Johnson Fistel Encourages EYPT Shareholders with Losses to Contact the Firm Regarding Investigation
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether EyePoint Pharmaceuticals, Inc. (“EyePoint” or “the Company”) (NASDAQ: EYPT), any of its executive officers, or others violated securities
Read more →EYPT▲ +10.1%on this news
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments – First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degenerat
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) Presented positive twelve-month safety and efficacy d
Read more →EYPT▼ -7.9%on this news
EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a confere
Read more →EYPTEyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert Technology Developments and Provide a Financial Update
- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 Annual Meeting - Phase 2 clinical trial (DAVIO 2) in wet AMD and in non-proliferative diabetic retinopathy (NPDR) patient dosing
Read more →EYPTEyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors
EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patient
Read more →EYPTEyePoint Pharmaceuticals to Host Investor Day on July 18, 2022
- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas - WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:
Read more →EYPTEyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert Technology Developments and Provide a Financial Update - Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EY
EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert Technology Developments and Provide a Financial Update -Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 A
Read more →EYPTEyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the election of Anthon
Read more →EYPTEyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therap
Read more →EYPT▼ -5.7%on this news
EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting
WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that a late-break
Read more →EYPTEyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chie
Read more →EYPT▲ +5.7%on this newsshared move
Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccu
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation May 2022 Exhibit 99.1 Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject
Read more →EYPTEyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan
- Betta Pharmaceuticals to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan; EyePoint retains all global ophthalmic rights for EYP-1901 elsewhere - - Partnership strengthens 2020 license agreement between EyePoint and Betta affiliate, Equinox Sciences, fo
Read more →EYPTEyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments - Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for E
EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments - Net product revenues of $9.0 million versus $6.8 million in Q1 2021, a 32% increase - - Management to host a conference call and webcast today at 8:30 a.m. ET -
Read more →EYPTEyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a confer
Read more →EYPTEyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference
WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Ch
Read more →EYPT▲ +6%on this news
EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank
WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has ente
Read more →EYPT▲ +5.1%on this news· ran to +22% by day 3shared move
EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer
WATERTOWN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment
Read more →EYPT▲ +15.3%on this news· ran to +34% by day 3shared move
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments
– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022, continuing positive safety and efficacy profile seen at six-month readout – Phase 2 trials for EYP-1901 in wet AMD and NPDR ar
Read more →EYPTEyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference
WATERTOWN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Ch
Read more →EYPTEyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a confere
Read more →EYPTEmployee - EyePoint Pharma Board of Directors - Sesen Bio - Hubble Tx Consultant - Aura Bio Financial Interest Disclosure - Jay S. Duker, M.D. Various statements made in this presentation are forward-looking, within the
Chief Operating Officer EyePoint Pharma 8-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert Implant for Previously Treated Wet AMD: The DAVIO Trial Exhibit 99.1 - Aura Bio Financial Interest Disclosure - Jay S. Duker, M.D. Various statements m
Read more →EYPTEyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments - Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudatio
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments - Phase 2 trials for EYP-1901 in wet AMD and NPDR are expected to initiate in Q3 2022 and 2H 2022, respectively, with top-line data from wet AMD tria
Read more →EYPT▼ -10.6%on this news· ran to -30% by day 3
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements
– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting – – Phase 2 study for EYP-1901 in wet AMD expected
Read more →EYPT▼ -10.6%on this news· ran to -30% by day 3
EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer
EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer WATERTOWN, Mass, January 10, 2022 (GLOBE NEWSWIRE) - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeu
Read more →EYPTEyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements - Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements - Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to b
Read more →EYPTEyePoint Pharmaceuticals and Harrow Health's ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU - ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU and absorb the m
EyePoint Pharmaceuticals and Harrow Health's ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU - ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU and absorb the majority of EyePoint's DEXYCU commercial organization; EyeP
Read more →EYPTEyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU
WATERTOWN, Mass. and NASHVILLE, Tenn. and CARLSBAD, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye di
Read more →EYPT▲ +5.2%on this news
EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering
WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of th
Read more →EYPT▲ +31%on this newsshared move
EyePoint Pharmaceuticals Announces Pricing of Public Offering
WATERTOWN, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an
Read more →EYPTEyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - Interim six-month results show positive safety data, no dose
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD WATERTOWN, Mass., November 13, 2021 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed t
Read more →EYPTEyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will h
Read more →EYPTEyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments - Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD fe
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments - Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) -
Read more →EYPT▲ +5.8%on this news· ran to +18% by day 3shared move
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer WATERTOWN, Mass., November 1, 2021 (GLOBE NEWSWIRE) - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the
Read more →EYPTEyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021
WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a confere
Read more →EYPT▲ +6.4%on this news
EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD – – YUTIQ® CALM registry study collecting real-world data on patients with fluocinolone acetonide intravitreal (FAi) implant 0.18 mg is ongoing – WATERTOWN, Mass., Oc
Read more →EYPT▲ +8.7%on this news
EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking
Read more →EYPTVarious statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation August 2021 Exhibit 99.1 Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statement
Read more →EYPT▲ +7%on this news
EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker
Read more →EYPTEyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; st
EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track for initial readout in Q4 2021 -Net p
Read more →EYPTEyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board
WATERTOWN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the formation of
Read more →EYPTEyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021
WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a co
Read more →EYPT▲ +8.5%on this news
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU
WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company
Read more →EYPTEyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive safety result
Read more →EYPTEyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU Intraocular Suspension, Approved by the American Medical Association
WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American
Read more →EYPTEyePoint Pharmaceuticals Joins Russell 2000 and Russell 3000 Index
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company
Read more →EYPTEyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker,
Read more →EYPTEyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the completion of
Read more →EYPTEyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments - EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remai
EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments - EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains on track for initial data in Q4 2021; -Completed $115.1
Read more →EYPTEyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021
WATERTOWN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a c
Read more →EYPTEyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments - $115.1 million follow-on financing completed in February 2021 - First patient dosed in P
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments - $115.1 million follow-on financing completed in February 2021 - First patient dosed in Phase 1 clinical trial with EYP-1901 in January 2021 - $16
Read more →EYPTEyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a co
Read more →EYPTEyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of an
Read more →EYPTEyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an
Read more →EYPTEyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD WATERTOWN, Mass., January 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and co
Read more →EYPTEyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration - - Anticipated Phase 1 clinical trial initiation in Q1 2021 - - Q4 2020 net product revenues are estimated to be
Read more →EYPTEyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics WATERTOWN, Mass., January 3, 2021 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmi
Read more →EYPTEyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues - IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal an
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues - IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degene
Read more →EYPTEyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation WATERTOWN, Mass., December 18, 2020 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative the
Read more →EYPTEyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it will effect a 1-for-10 reverse stock split at 5:00 p.m.
Read more →EYPTEyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
- No unexpected safety findings during the course of the study - - On track to file an IND by end of year; Phase 1 clinical trial to commence in early 2021 - WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical comp
Read more →EYPTEyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the f
Read more →EYPTEyePoint Pharmaceuticals Presents Positive Data of YUTIQ and DEXYCU in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
- Second Phase 3 trial of YUTIQ confirms 36-month positive efficacy results from the first Phase 3 trial - - Study of DEXYCU vs. Prednisolone eye drops shows high patient preference for DEXYCU regimen with statistically better inflammation control, pain, visual acuity outcomes
Read more →EYPTEyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selec
Read more →EYPTEyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments
- Total revenues of $15.7 million and net product revenues of $5.8 million - - Sequential quarterly increase in underlying customer demand of over 120% for DEXYCU® and over 5% for YUTIQ® - - EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment tar
Read more →EYPTEyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $15.7 million and net product revenues of $5.8 million - - Sequential quarterly incre
EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $15.7 million and net product revenues of $5.8 million - - Sequential quarterly increase in underlying customer demand of over 120% for DEXYCU
Read more →EYPTEyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter 2020 on Thursday, November 5, 2020. Ma
Read more →EYPTEyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants WATERTOWN, Mass., October 8, 2020 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalm
Read more →EYPTEyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020 - Q3 2020 net product revenues are estimated to be between $5.5 - $5.9 million, as healthcare facilities began reopening from COVI
EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020 - Q3 2020 net product revenues are estimated to be between $5.5 - $5.9 million, as healthcare facilities began reopening from COVID-19 closures - - Sequential increase in underlying custom
Read more →EYPTFORWARD LOOKING Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events
CANTOR VIRTUAL HEALTHCARE CONFERENCE SEPTEMBER 15, 2020 NASDAQ: EYPT Exhibit 99.1 FORWARD LOOKING Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that addr
Read more →EYPTEyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU
WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a purchase and marketing agreement with
Read more →EYPTEyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements WATERTOWN, Mass., August 20, 2020 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing i
Read more →EYPTEyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic
EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic - - U.S. commercial alliance with ImprimisRx to expand rea
Read more →EYPTEyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU
WATERTOWN, Mass. and NASHVILLE, Tenn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and ImprimisRx, the nation’s leading ophthalmic-focused out
Read more →EYPTEyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020. Ma
Read more →EYPTEyePoint Pharmaceuticals Presents Data Supporting YUTIQ at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting
WATERTOWN, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting YUTIQ® (fluocinolone acetoni
Read more →EYPTEyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer - World-renowned retina specialist to lead EYP-1901 development efforts and sup
EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer - World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint's ocular disease pipeline - WAT
Read more →EYPTEyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is sched
Read more →EYPTEyePoint Pharmaceuticals Presents Data Showcasing DEXYCU at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting
WATERTOWN, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of positive retrospective case study data suppor
Read more →EYPTEyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorg
EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments - Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled with recent financings supp
Read more →EYPTEyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter 2020 on Wednesday, May 6, 2020. Manag
Read more →EYPTSilicon Valley Bank U.S. Small Business Administration Paycheck Protection Program Note SBA Loan No. 2264207205 SBA Loan Name Borrower Legal Name EYEPOINT PHARMACEUTICALS US, INC. DBA Date 4/21/2020 Loan Amount $ 2041405
U.S. Small Business Administration Paycheck Protection Program SBA Loan No. 2264207205 SBA Loan Name Borrower Legal Name EYEPOINT PHARMACEUTICALS US, INC. DBA Date 4/21/2020 Loan Amount $ 2041405 Interest Rate 1.0% per annum Borrower EYEPOINT PHARMACEUTICALS US, INC. Operating
Read more →EYPTEyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update - Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities - -
EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update - Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities - - Reorganization of Commercial Operations to Align with Focu
Read more →EYPTEyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress - Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 - - Net produ
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress - Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 - - Net product revenues of $7.9 million in Q4 2019 and $16.8 million f
Read more →EYPTEyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ
WATERTOWN, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive topline 36-month follow-up data from the second Phase
Read more →EYPTEyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fourth quarter and full-year ended December 31, 2
Read more →EYPTVarious statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors o
INVESTOR PRESENTATION FEBRUARY 2020 NASDAQ: EYPT Exhibit 99.1 Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investor
Read more →EYPTEyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU
WATERTOWN, Mass. and NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Vision Center Network of America, LLC (“VCNA”), a Clinically
Read more →EYPTEyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion - EYP-1901 comb
EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion - EYP-1901 combines vorolanib with EyePoint's bioerodible Durasert technol
Read more →EYPTEyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan
WATERTOWN, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a fast-growing ophthalmology focused pharmaceuti
Read more →EYPTEyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues - Q4 2019 total revenues are estimated to be between $7.5 - $8.2 million and full-year 2019 total revenues are estimated to be bet
EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues - Q4 2019 total revenues are estimated to be between $7.5 - $8.2 million and full-year 2019 total revenues are estimated to be between $19.3 - $20.0 million - - Q4 2019 net product revenue
Read more →EYPTSAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assum
INVESTOR PRESENTATION JANUARY 2020 NASDAQ: EYPT Exhibit 99.1 SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate ass
Read more →EYPTEyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU Within One of the Largest Integrated Delivery Systems in the U.S.
WATERTOWN, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has entered into a formal two-year
Read more →EYPTEyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development - Veteran biopharmaceutical executive with broad experience at global companies brings more than 25 years of
EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development - Veteran biopharmaceutical executive with broad experience at global companies brings more than 25 years of finance, partnering and M&A experience to role - WATERTOW
Read more →EYPTEyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility WATERTOWN, MA
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility WATERTOWN, MA - November 19, 2019 - EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced a
Read more →EYPTEyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
WATERTOWN, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of George O. Elston as Chief Financi
Read more →EYPTEyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress - U.S. commercial launch trajectory for DEXYCU and YUTIQ gains momentum with strong customer order growth ove
EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress - U.S. commercial launch trajectory for DEXYCU and YUTIQ gains momentum with strong customer order growth over Q2 - - DEXYCU customer orders increased 207% over Q2 wit
Read more →EYPTEyePoint Pharmaceuticals Announces Addition of DEXYCU and YUTIQ to Department of Veteran Affairs Federal Supply Schedule
- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company commit
Read more →EYPTEyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU
WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a formal three-year contra
Read more →EYPTEyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter ended September 30, 2019 o
Read more →EYPTEyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ Now in Effect
WATERTOWN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the Company’s permanent and specific J-Code for
Read more →EYPTEyePoint Pharmaceuticals Announces YUTIQ Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ®
Read more →EYPTEyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Of
Read more →EYPTEyePoint Pharmaceuticals Announces Data Highlighting YUTIQ to be Presented at the 52nd Annual Retina Society Scientific Meeting
WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ®
Read more →EYPTForward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially
NASDAQ: EYPT Investor Presentation August 2019 Exhibit 99.1 Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially
Read more →EYPTEyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress Company reports total revenue of $7.2 million - Two commercial product launches in U.S. are underway for DEXYC
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress Company reports total revenue of $7.2 million - Two commercial product launches in U.S. are underway for DEXYCU and reps actively targeting uveitis specialists, cata
Read more →EYPTEyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
WATERTOWN, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting the Company's Y
Read more →EYPTEyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ by the Center for Medicare and Medicaid Services (CMS)
WATERTOWN, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services
Read more →EYPTEyePoint Pharmaceuticals Announces Second Quarter 2019 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., July 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter ended June 30, 2019 on We
Read more →EYPTEyePoint Pharmaceuticals Announces Data Highlighting YUTIQ to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
WATERTOWN, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ
Read more →EYPTEyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors Ms. DiCicco is a Veteran Healthcare Executive with 30 Years of Financial and Corporate Development Experience WATERTOWN, MA
EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors Ms. DiCicco is a Veteran Healthcare Executive with 30 Years of Financial and Corporate Development Experience WATERTOWN, MA July 15, 2019 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopha
Read more →EYPTEyePoint Pharmaceuticals Added to Russell 3000 and 2000 Indexes
WATERTOWN, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) (“Eyepoint”), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has joined the broad-
Read more →EYPTEyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to Scott Jones, EyePoi
Read more →EYPTEyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires
- Scott Jones Appointed as Chief Commercial Officer - - Said Saim, Ph.D., Appointed as Chief Technology Officer - WATERTOWN, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and
Read more →EYPTEyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
WATERTOWN, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Offi
Read more →EYPTEyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress - YUTIQ and DEXYCU commercially launched in 1Q2019 - - YUTIQ recommended for specific J-code by Centers for Med
EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress DEXYCU commercially launched in 1Q2019 - - YUTIQ recommended for specific J-code by Centers for Medicare & Medicaid Services - and equity public offering generated ne
Read more →EYPTEyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
– 36-month data showed a uveitis eye flare recurrence rate of 56.3% in YUTIQ-treated eyes vs. 92.9% in sham eyes - – Durability of 36-month data and safety support long-term efficacy of YUTIQ - WATERTOWN, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (N
Read more →EYPTEyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter ended March 31, 2019 on W
Read more →EYPTEyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of DEXYCU™ to be presented at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) and Ameri
Read more →EYPTEyePoint Pharmaceuticals Reports Fiscal Period Ended
EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments -YUTIQTM and DEXYCUTM commercially launched in 1Q2019 -$60 million debt facility secured to support YUTIQ and DEXYCU commercial
Read more →EYPTEyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%
WATERTOWN, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has commercially launched DEXYCUTM (dexamet
Read more →EYPTEyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal period ended December 31, 2018 on
Read more →EYPTEyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility Provides support for the product launches of YUTIQ TM and
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility Provides support for the product launches of YUTIQTM and DEXYCUTM WATERTOWN, MA February 13, 2019 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and co
Read more →EYPTEyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
WATERTOWN, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it has commercially launched YUTIQTM in the United
Read more →EYPTEyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors Dr. Guyer is a Successful Ophthalmology Entrepreneur with Deep Business and Clinical Experience in Advancing Treatments for Ocular Diseases - WAT
EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors Dr. Guyer is a Successful Ophthalmology Entrepreneur with Deep Business and Clinical Experience in Advancing Treatments for WATERTOWN, MA January 28, 2019 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a
Read more →EYPTEyePoint Pharmaceuticals Provides 2019 Commercial Update - DEXYCU TM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - - YUTIQ TM commercial launch on track for 1Q19
EyePoint Pharmaceuticals Provides 2019 Commercial Update - DEXYCUTM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - YUTIQTM commercial launch on track for 1Q19 - WATERTOWN, Mass., January 3, 2019 EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialt
Read more →EYPTEyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
WATERTOWN, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has been selected for addition to the NASDAQ Biot
Read more →EYPTEyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
- Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position - WATERTOWN, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developi
Read more →EYPTEyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
WATERTOWN, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services
Read more →EYPTEyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments -YUTIQ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive licens
EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments -YUTIQ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and comme
Read more →EYPTEyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
WATERTOWN, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Off
Read more →EYPTEyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agr
Read more →EYPTEyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter of fiscal year 2019 on Tue
Read more →EYPTEyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors - Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience
EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors - Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience - WATERTOWN, Mass., October 30, 2018 EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical com
Read more →EYPTEyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
WATERTOWN, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of 24-month efficacy and safety data sup
Read more →EYPTEyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
- Five oral abstracts to be presented at annual meeting and subspecialty days – -24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceu
Read more →EYPTEyePoint Pharmaceuticals Receives FDA Approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg - The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, no
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ (fluocinolone acetonide intravitreal - The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness
Read more →EYPTEyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
WATERTOWN, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 mill
Read more →EYPTEyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress -Substantial progress made in the Company s accelerated transformation into a commercial entity -YU
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress -Substantial progress made in the Company s accelerated transformation into a commercial entity -YUTIQTM PDUFA date of November 5, 2018 -Commercial preparat
Read more →EYPTEyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of calendar year 2019 -Balance sheet strengthened by $35 million of
Read more →EYPTEyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™
WATERTOWN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS)
Read more →EYPTEyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal 2018 fourth quarter and full yea
Read more →EYPTEyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality
WATERTOWN, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of John Weet, Ph.D. as Senior Vice P
Read more →EYPTEyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that David Price, Chief Financial Officer, is schedu
Read more →EYPTEyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer Seasoned financial executive brings more than 25 years of diverse financial and operational experience WATERTOWN, MA
EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer Seasoned financial executive brings more than 25 years of diverse financial and operational experience August 1, 2018 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company co
Read more →EYPTEyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
YUTIQ™ delivers positive twelve month efficacy vs sham with reduced rates of recurrence and reduced use of rescue therapies in patients with noninfectious posterior segment uveitis NDA currently under review by FDA; PDUFA action date of November 5, 2018 WATERTOWN, Mass., July 2
Read more →EYPTEyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
WATERTOWN, Mass., July 11, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ™
Read more →EYPTEyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing
Expected closing of $25.5 million in capital to be used to accelerate EyePoint’s transformation into a commercial-stage specialty biopharmaceutical company Financing supports two near-term product launches anticipated in the first half of 2019 WATERTOWN, Mass., June 25, 2018 (G
Read more →EYPTIntroduction Our Business We are a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Our lead product, DEXYCU (dexamethasone
We are a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Our lead product, DEXYCU (dexamethasone intraocular suspension) 9%, approved by the U.S. Food and Drug Administration ( FDA
Read more →EYPTEyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
WATERTOWN, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of Leonard M. Blum as Executive Vice
Read more →EYPTEyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results Completed Substantive Strategic Initiatives to Accelerate Transformation to a Commercial Company Conference Call and Webcast Today, May 8th, at 4:30 p.m.
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results Completed Substantive Strategic Initiatives to Accelerate Transformation to a Commercial Company Conference Call and Webcast Today, May 8th, at 4:30 p.m. ET WATERTOWN, Mass., May 8, 2018 EyePoint Pharmaceutical
Read more →EYPTEyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year
Read more →EYPTEyePoint Pharmaceuticals’ YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
WATERTOWN, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUT
Read more →EYPTEyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
WATERTOWN, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the U.S. Patent and Trademark Office
Read more →EYPTpSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners Company Will Rebrand as EyePoint Pharmaceuticals, Inc. Acquisition and addi
pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners Company Will Rebrand as EyePoint Pharmaceuticals, Inc. Acquisition and additional funding significantly accelerate the company s tra
Read more →EYPTpSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert Three-Year Treatment for Posterior Segment Uveitis
pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert Three-Year Treatment for Posterior Segment Uveitis WATERTOWN, Mass., March 19, 2018 (GLOBE NEWSWIRE) pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release d
Read more →EYPTpSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive E
pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months Awaiti
Read more →EYPTpSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early Ja
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7t
Read more →EYPTpSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call
pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call and Webcast Today, September 11th, at 4:30 p.m. ET WATERTOWN, Mas
Read more →EYPTpSivida Out-licenses EMEA Rights for Durasert Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN Improves pSivida s
pSivida Out-licenses EMEA Rights for Durasert Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN Improves pSivida s Revenue WATERTOWN, MA., July 10, 2017 pSivida Corp. (NASDA
Read more →EYPTpSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson Mass., June 28, 2017 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peter
Read more →EYPTpSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union
pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union Mass., June 22, 2017 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug produ
Read more →EYPTpSivida s Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study Highly Significant Difference Observed Between Durasert and Control Group in P
pSivida s Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurre
Read more →EYPTpSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track EU and US Calendar 2017 Registration Filing Milestones for Durasert for Posterior Segment Uveitis Remain on Schedule Conference Call and We
pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones Calendar 2017 Registration Filing Milestones for Durasert for Posterior Segment Uveitis Remain on Schedule Conference Call and Webcast Today, May 4th, at 4:30 p.m. ET WATERTOWN, Mass., May 4, 2017 pSivida
Read more →EYPTpSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results EU and U.S. 2017 Registration Filing Milestones for Durasert for Posterior Segment Uveitis Remain on Track Conference Call and Webcast Today, Februa
pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results EU and U.S. 2017 Registration Filing Milestones for Durasert for Posterior Segment Uveitis Remain on Track Conference Call and Webcast Today, February 7, at 4:30 p.m. ET WATERTOWN, Mass., February 7, 2017
Read more →EYPTSeasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development WATERTOWN, Mass., November 7, 2016 pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced that De
Read more →EYPTpSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline New Leadership Focused on Increasing Commercial Potential of Proven Durasert Sustained Release Plat
pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & New Leadership Focused on Increasing Commercial Potential of Proven Durasert Sustained Release Platform Company Continues Focus on MAA and NDA Filings for Uveitis Product in 20
Read more →EYPTpSivida Implements Leadership Change Nancy Lurker Named as President and CEO Watertown, MA, (
pSivida Implements Leadership Change Nancy Lurker Named as President and CEO Watertown, MA, (September 15, 2016) pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its Board o
Read more →EYPTPSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FY 2016
PSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FY 2016 RESULTS WATERTOWN, MA September 12, 2016 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Com
Read more →EYPTpSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Plan to Facilitate Product Development and Reduce Operating Expenses Watertown, MA (
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Plan to Facilitate Product Development and Reduce Operating Expenses Watertown, MA (July 15, 2016) pSivida Corp (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained rel
Read more →EYPTPSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS THIRD QUARTER FY 2016
PSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS THIRD QUARTER FY 2016 RESULTS WATERTOWN, MA May 5, 2016 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update
Read more →EYPTPSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS SECOND QUARTER FY 2016
PSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS SECOND QUARTER FY 2016 RESULTS WATERTOWN, MA February 8, 2016 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company u
Read more →EYPTPSIVIDA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK WATERTOWN, Mass. (
PSIVIDA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK WATERTOWN, Mass. (January 6, 2016) pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and
Read more →EYPTpSivida s Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p 0.00000001) Statistical Significance in Improvement in Visual Acuity a
pSivida s Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p < 0.00000001) Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy Positive Safety Data
Read more →EYPTPSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS FIRST QUARTER FY 2016
PSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS FIRST QUARTER FY 2016 RESULTS WATERTOWN, MA November 5, 2015 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company u
Read more →EYPTPSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FY 2015
PSIVIDA CORP. PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FY 2015 RESULTS WATERTOWN, MA September 9, 2015 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Comp
Read more →EYPTPSIVIDA CORP. REPORTS THIRD QUARTER FY 2015 RESULTS Clear FDA Regulatory Path for Medidur for Posterior Uveitis NDA Filing Planned in First Half of 2017 WATERTOWN, MA
PSIVIDA CORP. REPORTS THIRD QUARTER FY 2015 RESULTS Clear FDA Regulatory Path for Medidur for Posterior Uveitis NDA Filing Planned in First Half of 2017 WATERTOWN, MA May 8, 2015 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug de
Read more →EYPTPSIVIDA CORP. REPORTS SECOND QUARTER FY 2015
PSIVIDA CORP. REPORTS SECOND QUARTER WATERTOWN, MA February 5, 2015 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended Decembe
Read more →EYPTPSIVIDA CORP. REPORTS FIRST QUARTER FY 2015
PSIVIDA CORP. REPORTS FIRST QUARTER FY 2015 RESULTS WATERTOWN, MA November 7, 2014 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter
Read more →EYPTpSIVIDA CORP. REPORTS FDA APPROVAL OF ILUVIEN FOR DIABETIC MACULAR EDEMA pSivida earns $25 million milestone WATERTOWN, Mass. (BUSINESS WIRE) pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustain
pSIVIDA CORP. REPORTS FDA APPROVAL OF ILUVIEN FOR DIABETIC MACULAR EDEMA pSivida earns $25 million milestone WATERTOWN, Mass. (BUSINESS WIRE) pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye dise
Read more →EYPTPSIVIDA CORP. REPORTS FOURTH QUARTER AND FY 2014
PSIVIDA CORP. REPORTS FOURTH QUARTER AND FY 2014 RESULTS WATERTOWN, MA September 9, 2014 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its fourth
Read more →EYPTPSIVIDA CORP. REPORTS THIRD QUARTER 2014 RESULTS Now Plans to Seek US approval of Medidur for Posterior Uveitis Based on One Phase III Trial WATERTOWN, MA
PSIVIDA CORP. REPORTS THIRD QUARTER 2014 RESULTS Now Plans to Seek US approval of Medidur for Posterior Uveitis Based on One Phase III Trial WATERTOWN, MA May 13, 2014 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery produc
Read more →EYPTSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of March 13, 2014, between pSivida Corp., a Delaware corporation (the Company ), and the purchaser identified on the signature page hereto (including its successors and assigns, the P
Read more →EYPTPSIVIDA CORP. REPORTS SECOND QUARTER 2014
PSIVIDA CORP. REPORTS SECOND QUARTER WATERTOWN, MA February 7, 2014 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended Decembe
Read more →EYPTPSIVIDA CORP. REPORTS FDA LABELING DISCUSSIONS FOR ILUVIEN FOR DME
PSIVIDA CORP. REPORTS FDA LABELING DISCUSSIONS FOR ILUVIEN FOR DME; ADVISORY COMMITTEE MEETING NO WATERTOWN, Mass., December 18, 2013 (BUSINESS WIRE) pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating e
Read more →EYPTPSIVIDA CORP. REPORTS FIRST QUARTER 2014
PSIVIDA CORP. REPORTS FIRST QUARTER WATERTOWN, MA November 12, 2013 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended Septembe
Read more →EYPTPSIVIDA REPORTS COMPLETE RESPONSE LETTER FROM FDA FOR ILUVIEN Watertown, MA (
PSIVIDA REPORTS COMPLETE RESPONSE LETTER FROM FDA FOR ILUVIEN Watertown, MA (October 18, 2013) pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today anno
Read more →EYPTPSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2013
PSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2013 RESULTS WATERTOWN, MA September 25, 2013 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial resu
Read more →EYPTPSIVIDA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Watertown, Massachusetts
PSIVIDA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Watertown, Massachusetts July 18, 2013 pSivida Corp. (Nasdaq: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announ
Read more →EYPTPSIVIDA CORP. REPORTS THIRD QUARTER FISCAL YEAR 2013
PSIVIDA CORP. REPORTS THIRD QUARTER FISCAL YEAR 2013 RESULTS WATERTOWN, MA May 13, 2013 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its
Read more →EYPTpSivida Reports Updates on ILUVIEN for Planned Resubmission to FDA and European Launch
pSivida Reports Updates on ILUVIEN for Planned Resubmission to FDA and European Launch WATERTOWN, Mass. March 22, 2013 (BUSINESS WIRE) pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic dr
Read more →EYPTPSIVIDA CORP. REPORTS SECOND QUARTER FISCAL YEAR 2013
PSIVIDA CORP. REPORTS SECOND QUARTER FISCAL YEAR 2013 RESULTS WATERTOWN, MA February 6, 2013 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results fo
Read more →EYPTPSIVIDA CORP. REPORTS FIRST QUARTER FISCAL YEAR 2013
PSIVIDA CORP. REPORTS FIRST QUARTER FISCAL YEAR 2013 RESULTS WATERTOWN, MA November 8, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for
Read more →EYPTPSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2012
PSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2012 RESULTS WATERTOWN, MA September 24, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial resu
Read more →EYPTpSivida Corp. Reports Alimera s Intention to Resubmit Application to FDA for ILUVIEN in DME Using Data from Completed Trials WATERTOWN, MA
pSivida Corp. Reports Alimera s Intention to Resubmit Application to FDA for ILUVIEN in DME Using Data from Completed Trials WATERTOWN, MA, August 1, 2012 - pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment o
Read more →EYPTPSIVIDA CORP. RECEIVES FDA CLEARANCE FOR PIVOTAL TRIALS FOR INJECTABLE SUSTAINED- RELEASE MICRO-INSERT
PSIVIDA CORP. RECEIVES FDA CLEARANCE FOR PIVOTAL TRIALS FOR INJECTABLE SUSTAINED- RELEASE MICRO-INSERT TO TREAT UVEITIS WATERTOWN, MA, July 19, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-o
Read more →EYPTPSIVIDA S
PSIVIDA S PARTNER ALIMERA SCIENCES ANNOUNCES AN AGREEMENT TO RAISE CAPITAL TO FUND THE DEVELOPMENT AND COMMERCIALIZATION OF ILUVIEN WATERTOWN, MA, July 18, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatme
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE THIRD QUARTER ENDED MARCH 31, 2012 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE THIRD QUARTER ENDED MARCH 31, 2012 WATERTOWN, MA May 9, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial resu
Read more →EYPTPSIVIDA CORP. ANNOUNCES POSITIVE OUTCOME TO EUROPEAN DECENTRALIZED PROCEDURE FOR APPROVAL OF ILUVIEN FOR THE TREATMENT OF CHRONIC DIABETIC MACULAR EDEMA ILUVIEN expected to be the first sustained release pharmaceutical i
PSIVIDA CORP. ANNOUNCES POSITIVE OUTCOME TO EUROPEAN DECENTRALIZED PROCEDURE FOR APPROVAL OF ILUVIEN FOR THE TREATMENT OF CHRONIC DIABETIC MACULAR EDEMA WATERTOWN, MA February 28, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug deliv
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2011 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2011 WATERTOWN, MA February 8, 2012 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced finan
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2011 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2011 WATERTOWN, MA November 7, 2011 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced finan
Read more →EYPTPSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2011
PSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2011 RESULTS WATERTOWN, MA September 12, 2011 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including clinical stage produ
Read more →EYPTpSivida Announces Opening of Investigator-Sponsored Trial for Injectable, Sustained Release FAc Insert for Posterior Uveitis Watertown, MA, USA (
pSivida Announces Opening of Investigator-Sponsored Trial for Injectable, Sustained Release FAc Insert for Posterior Uveitis Watertown, MA, USA (September 12, 2011) Drug delivery company pSivida Corp. (NASDAQ:PSDV, ASX:PVA) today announced the opening of an investigational new
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE THIRD QUARTER ENDED MARCH 31, 2011 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE THIRD QUARTER ENDED MARCH 31, 2011 May 10, 2011 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUVIEN for
Read more →EYPTPSIVIDA ANNOUNCES NEW SAFETY AND EFFICACY DATA FROM PHASE 3
PSIVIDA ANNOUNCES NEW SAFETY AND EFFICACY DATA FROM PHASE 3 ILUVIEN IN DIABETIC MACULAR EDEMA WATERTOWN, MA, May 03, 2011 (BUSINESS WIRE) pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye d
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2010 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2010 February 9, 2011 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUV
Read more →EYPTPSIVIDA ANNOUNCES POSITIVE RESULTS FROM THE 36 MONTH READOUT OF COMPLETED PHASE 3
PSIVIDA ANNOUNCES POSITIVE RESULTS FROM THE 36 MONTH READOUT OF COMPLETED PHASE 3 FAME STUDY OF ILUVIEN IN PATIENTS WITH DIABETIC MACULAR EDEMA WATERTOWN, Mass., Feb 03, 2011 (BUSINESS WIRE) pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug de
Read more →EYPTRodman & Renshaw Letterhead]
[Rodman & Renshaw Letterhead] Attn: Paul Ashton, Ph.D. Chief Executive Officer Ladies and Gentlemen: This letter (the Agreement ) constitutes the agreement between Rodman & Renshaw, LLC ( Rodman or the Placement Agent ) and pSivida Corp. (the Company ), that Rodman shall ser
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2010 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2010 WATERTOWN, MA November 5, 2010 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product
Read more →EYPTPSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2010 FINANCIAL RESULTS - Iluvien NDA Filed and Granted Priority Review WATERTOWN, MA
PSIVIDA CORP. REPORTS FOURTH QUARTER AND FISCAL YEAR 2010 FINANCIAL RESULTS - Iluvien NDA Filed and Granted Priority Review September 22, 2010 pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back of the e
Read more →EYPTPSIVIDA CORP. REPORTS THIRD QUARTER FISCAL YEAR 2010 FINANCIAL RESULTS - $15.2m received from Alimera in full payment of conditional note after end of quarter. WATERTOWN, MA
PSIVIDA CORP. REPORTS THIRD QUARTER FISCAL YEAR 2010 FINANCIAL RESULTS - $15.2m received from Alimera in full payment of conditional note after end of quarter. WATERTOWN, MA May 12, 2010 pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with two of the on
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2009 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2009 WATERTOWN, MA February 11, 2010 pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA f
Read more →EYPTIluvien Clinical Development Program and certain risk factors relating to the Iluvien Clinical Development program from Form S-1/A of Alimera, Registration No. 333-162782, filed
Iluvien Clinical Development Program and certain risk factors relating to the Iluvien Clinical Development program from Form S-1/A of Alimera, Registration No. 333-162782, filed December 23, 2009 Clinical Development Program The following table summarizes current and planned
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2009 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2009 WATERTOWN, MA November 12, 2009 pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA f
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2009 WATERTOWN, MA
PSIVIDA CORP. REPORTS RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED JUNE 30, 2009 WATERTOWN, MA September 24, 2009 pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved
Read more →EYPTPSIVIDA CORP. REPORTS RESULTS FOR THE THIRD QUARTER ENDED MARCH 31, 2009 Iluvien NDA filing remains on schedule for early calendar 2010 Positive 12 month interim safety and efficacy data from Iluvien PK study WATERTOWN,
PSIVIDA CORP. REPORTS RESULTS FOR THE THIRD QUARTER ENDED MARCH 31, 2009 Iluvien NDA filing remains on schedule for early Positive 12 month interim safety and efficacy data from Iluvien PK study WATERTOWN, MA May 13, 2009 pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a dru
Read more →Competitive Position
How EYPT ranks across every disease it competes inCompetitive Position is a premium feature
See how EYPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial